BRPI0819434A2 - método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal - Google Patents

método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal

Info

Publication number
BRPI0819434A2
BRPI0819434A2 BRPI0819434A BRPI0819434A BRPI0819434A2 BR PI0819434 A2 BRPI0819434 A2 BR PI0819434A2 BR PI0819434 A BRPI0819434 A BR PI0819434A BR PI0819434 A BRPI0819434 A BR PI0819434A BR PI0819434 A2 BRPI0819434 A2 BR PI0819434A2
Authority
BR
Brazil
Prior art keywords
proliferation
prevention
treatment
under conditions
liver disease
Prior art date
Application number
BRPI0819434A
Other languages
English (en)
Inventor
J Schwartz Jason
P Kennedy Thomas
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of BRPI0819434A2 publication Critical patent/BRPI0819434A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0819434A 2007-11-08 2008-11-10 método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal BRPI0819434A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98636207P 2007-11-08 2007-11-08
PCT/US2008/083028 WO2009062174A1 (en) 2007-11-08 2008-11-10 Use of angiogenesis antagonists in conditions of abnormal venous proliferation

Publications (1)

Publication Number Publication Date
BRPI0819434A2 true BRPI0819434A2 (pt) 2019-09-24

Family

ID=40626233

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819434A BRPI0819434A2 (pt) 2007-11-08 2008-11-10 método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal

Country Status (4)

Country Link
US (2) US20110003890A1 (pt)
EP (1) EP2214709A4 (pt)
BR (1) BRPI0819434A2 (pt)
WO (1) WO2009062174A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980251B2 (en) * 2013-02-23 2015-03-17 Stemnion, Inc. Methods for preventing and treating hemorrhoids
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
US10755078B2 (en) * 2015-04-10 2020-08-25 President And Fellows Of Harvard College Methods and devices for live cell imaging analysis
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
CN105825070A (zh) * 2016-04-06 2016-08-03 南方医科大学南方医院 一种虚拟肝静脉压力梯度的测量方法
JP6289773B1 (ja) * 2017-05-19 2018-03-07 花王株式会社 茶飲料
CA3103432A1 (en) * 2018-06-27 2020-01-02 Children's Medical Center Corporation Compounds for inhibition of inflammation
AU2020279395B2 (en) 2019-05-22 2025-08-28 Biovie Inc. Formulations of terlipressin
WO2022035813A1 (en) * 2020-08-10 2022-02-17 Reverspah Llc Method and composition for treating corona virus, influenza, and acute respiratory distress syndrome
US11033516B1 (en) 2020-09-18 2021-06-15 Spring Discovery, Inc. Combination therapies with disulfiram
CN120604752B (zh) * 2025-06-16 2026-02-06 河南省人民医院 视网膜色素变性模型的构建方法和试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03232870A (ja) * 1990-02-06 1991-10-16 Taisho Pharmaceut Co Ltd チオアミド化合物
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20040022788A1 (en) * 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
US20030181495A1 (en) * 1998-06-23 2003-09-25 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
GB2381272B (en) * 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Diagnosis and treatment of atherosclerosis
US20050180952A1 (en) * 2003-08-26 2005-08-18 Pettis Ronald J. Methods for intradermal delivery of therapeutics agents
EP3153159A1 (en) * 2004-07-09 2017-04-12 Robert Sabin Compositions comprising a copper compound for treatment of mammalian diseases
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
SI2032134T1 (sl) * 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida

Also Published As

Publication number Publication date
US20110003890A1 (en) 2011-01-06
EP2214709A4 (en) 2011-05-11
EP2214709A1 (en) 2010-08-11
WO2009062174A1 (en) 2009-05-14
US20140161906A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
BRPI0819434A2 (pt) método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
DK2464362T3 (da) Probiotisk præparat til forebyggelse eller behandling af mavetarmlidelser hos hunde
SI3888584T1 (sl) Sistemi za zdravljenje zobnih ali paradontalnih težav
BRPI0907422A2 (pt) Composições de limpeza e/ou tratamento
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
IL242169A0 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
DK2137307T3 (da) Termostabile asparaginaser
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
BRPI0807667A2 (pt) Composição emulsificada de óleo-em-água
BRPI0816836A2 (pt) Composições de limpeza e/ou tratamento
HRP20171012T1 (hr) Fungicidni pripravak i postupak za suzbijanje štetnih gljiva
EP2485749A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0911083A2 (pt) métodos para o tratamento ou prenvenção de diabetes mullitus e outros desequilíbrios metabólicos
FR2951637B1 (fr) Table pour massages de personnes allongees ou assises.
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
DK2081950T3 (da) Med irinotecanbehandling forbundne ekspressionsprofiler
BRPI0906492A2 (pt) antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0814346A2 (pt) Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr.
NL2002588A1 (nl) Safety glasses for clean rooms and method for securing same.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.